SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oscient Pharmaceuticals Corp. (OSCI) -- Ignore unavailable to you. Want to Upgrade?

To: Chip McVickar who wrote (884)5/24/2001 9:25:29 AM
From: Sara  Read Replies (1) | Respond to of 1154
 
C O R R E C T I O N -- Friedman, Billings, Ramsey & Co., Inc./

PR Newswire
In DCTH050, FBR Report Analyzes Market Potential of Genomics Sector, moved
earlier today, we are advised by the company that the fourth graph, 7th bullet,
should read "Myriad Genetics, Inc. (Nasdaq: MYGN) with a "Buy" rating and a
12-month target of $71 per share."



To: Chip McVickar who wrote (884)6/6/2001 1:34:28 PM
From: Chip McVickar  Read Replies (1) | Respond to of 1154
 
Air Head Post


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News